RNA-based liquid biopsy in head and neck cancer

J Kabzinski, A Kucharska-Lusina, I Majsterek - Cells, 2023 - mdpi.com
Head and neck cancer (HNC) is a prevalent and diverse group of malignancies with
substantial morbidity and mortality rates. Early detection and monitoring of HNC are crucial …

Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity

GS Kinker, AC Greenwald, R Tal, Z Orlova, MS Cuoco… - Nature …, 2020 - nature.com
Cultured cell lines are the workhorse of cancer research, but the extent to which they
recapitulate the heterogeneity observed among malignant cells in tumors is unclear. Here …

Precision medicine approaches to overcome resistance to therapy in head and neck cancers

S Ortiz-Cuaran, J Bouaoud, A Karabajakian… - Frontiers in …, 2021 - frontiersin.org
Head and neck squamous cell carcinoma (HNSCC) is the sixth most incident cancer
worldwide. More than half of HNSCC patients experience locoregional or distant relapse to …

A transcriptomic map of EGFR-induced epithelial-to-mesenchymal transition identifies prognostic and therapeutic targets for head and neck cancer

H Schinke, E Shi, Z Lin, T Quadt, G Kranz, J Zhou… - Molecular Cancer, 2022 - Springer
Background Epidermal growth factor receptor (EGFR) is both a driver oncogene and a
therapeutic target in advanced head and neck squamous cell carcinoma (HNSCC) …

BET inhibition overcomes receptor tyrosine kinase–mediated cetuximab resistance in HNSCC

B Leonard, TM Brand, RA O'Keefe, ED Lee, Y Zeng… - Cancer research, 2018 - AACR
Cetuximab, the FDA-approved anti-EGFR antibody for head and neck squamous cell
carcinoma (HNSCC), has displayed limited efficacy due to the emergence of intrinsic and …

Enabling Single‐Cell Drug Response Annotations from Bulk RNA‐Seq Using SCAD

Z Zheng, J Chen, X Chen, L Huang, W **e… - Advanced …, 2023 - Wiley Online Library
The single‐cell RNA sequencing (scRNA‐seq) quantifies the gene expression of individual
cells, while the bulk RNA sequencing (bulk RNA‐seq) characterizes the mixed transcriptome …

DDX3 activates CBC-eIF3–mediated translation of uORF-containing oncogenic mRNAs to promote metastasis in HNSCC

HH Chen, HI Yu, MH Yang, WY Tarn - Cancer research, 2018 - AACR
Mutated or dysregulated DDX3 participates in the progression and metastasis of cancer via
its multiple roles in regulating gene expression and cellular signaling. Here, we show that …

Therapy-related transcriptional subtypes in matched primary and recurrent head and neck cancer

P Weber, A Künstner, J Hess, K Unger… - Clinical Cancer …, 2022 - AACR
Purpose: The genetic relatedness between primary and recurrent head and neck squamous
cell carcinomas (HNSCC) reflects the extent of heterogeneity and therapy-driven selection of …

TGF-beta-activated cancer-associated fibroblasts limit cetuximab efficacy in preclinical models of head and neck cancer

KM Yegodayev, O Novoplansky, A Golden, M Prasad… - Cancers, 2020 - mdpi.com
Most head and neck cancer (HNC) patients are resistant to cetuximab, an antibody against
the epidermal growth factor receptor. Such therapy resistance is known to be mediated, in …

Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway

R Garcia-Escudero, C Segrelles, M Duenas, M Pombo… - Oral Oncology, 2018 - Elsevier
Objectives Phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) is commonly
altered in many human tumors, leading to the activation of p110α enzymatic activity that …